Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Oral Busulfan and Cyclophosphamide or IV Busulfan and Fludarabine for Allogeneic HSCT in Hematologic Malignancies?.

J. Altman, N. Venepalli, J. Monreal, K. Rashid, L. Gordon, J. Winter, S. Williams, M. Tallman, O. Frankfurt, A. Evens, S. Singhal, J. Mehta

Blood (2006) 108 (11): 2940.

https://doi.org/10.1182/blood.V108.11.2940.2940

Published: 2006

Journal Articles

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Treating Hyperuricemia in Patients with Hematologic Malignancies.

S. Trifilio, A. Evens, L. Gordon, S. Singhal, M. Tallman, J. Mehta

Blood (2005) 106 (11): 3123.

https://doi.org/10.1182/blood.V106.11.3123.3123

Published: 2005

Journal Articles

Graft CD3+ Cell Content Affects Acute GVHD after Submyeloablative Allogeneic HSCT.

Seema Singhal, A. Evens, O. Frankfurt, L. Gordon, R. Meagher, M. Tallman, S. Williams, J. Winter, L. Kaminer, D. Grinblatt, J. Mehta

Blood (2005) 106 (11): 3663.

https://doi.org/10.1182/blood.V106.11.3663.3663

Published: 2005

Journal Articles

Ideal (IBW) Rather Than Actual (ABW) Body Weight Should Be Used To Calculate Cell Dose in Allogeneic HSCT.

Seema Singhal, A. Evens, O. Frankfurt, L. Gordon, R. Meagher, M. Tallman, S. Williams, J. Winter, D. Grinblatt, L. Kaminer, J. Mehta

Blood (2005) 106 (11): 1765.

https://doi.org/10.1182/blood.V106.11.1765.1765

Published: 2005

Journal Articles

Outcome of Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Development of a Prognostic Model Based on Pre-Transplant Characteristics.

Jayesh Mehta, A. Evens, O. Frankfurt, L. Gordon, D. Grinblatt, L. Kaminer, R. Meagher, M. Tallman, S. Williams, J. Winter, S. Singhal

Blood (2005) 106 (11): 1145.

https://doi.org/10.1182/blood.V106.11.1145.1145

Published: 2005

Journal Articles

The Effect of the Platelet Content of Blood Stem Cell Grafts on GVHD.

Jayesh Mehta, R. Meagher, A. Evens, O. Frankfurt, S. Singhal, M. Tallman, S. Williams, J. Winter, D. Grinblatt, L. Kaminer, L. Gordon

Blood (2005) 106 (11): 1077.

https://doi.org/10.1182/blood.V106.11.1077.1077

Published: 2005

Journal Articles

Identifying Patients at Risk of Early Relapse after Submyeloablative Allogeneic HSCT.

Jayesh Mehta, L. Gordon, M. Tallman, J. Winter, S. Williams, A. Evens, O. Frankfurt, D. Grinblatt, L. Kaminer, R. Meagher, S. Singhal

Blood (2005) 106 (11): 5390.

https://doi.org/10.1182/blood.V106.11.5390.5390

Published: 2005

Journal Articles

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Hyperuricemia.

S. Trifilio, M. Tallman, S. Singhal, L. Gordon, A. Evens, J. Mehta

Blood (2004) 104 (11): 3312.

https://doi.org/10.1182/blood.V104.11.3312.3312

Published: 2004

Journal Articles

Pre-Transplant Variables Affecting the Outcome of Submyeloablative Allogeneic HSCT in Uniformly Treated Patients with Hematologic Malignancies.

Jayesh Mehta, S. Singhal, M. Tallman, S. Williams, J. Winter, A. Evens, D. Grinblatt, L. Kaminer, L. Gordon

Blood (2004) 104 (11): 2324.

https://doi.org/10.1182/blood.V104.11.2324.2324

Published: 2004

Journal Articles

Is a Younger 10-Allele-Matched Unrelated Donor (MUD) Better Than an Older 6-Antigen-Matched Sibling Donor (MSD) for Allogeneic HSCT?.

Jayesh Mehta, L. Gordon, M. Tallman, J. Winter, S. Williams, A. Evens, D. Grinblatt, L. Kaminer, S. Singhal

Blood (2004) 104 (11): 2757.

https://doi.org/10.1182/blood.V104.11.2757.2757

Published: 2004

Journal Articles

The CD34+ Cell Dose, Even in an "Acceptable" Range, Affects Outcome of Allogeneic Blood Stem Cell Transplantation.

Seema Singhal, L. Gordon, R. Meagher, A. Evens, M. Tallman, S. Williams, J. Winter, D. Grinblatt, L. Kaminer, J. Mehta

Blood (2004) 104 (11): 1153.

https://doi.org/10.1182/blood.V104.11.1153.1153

Published: 2004

Journal Articles

Does Concomitant Methotrexate (MTX) and GM-CSF Administration after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Predispose to Thrombotic Microangiopathy (TMA)?.

Jayesh Mehta, H. Kwaan, L. Gordon, A. Evens, S. Singhal, J. Winter, S. Williams, J. Rowe, A. Goldstone, M. Tallman

Blood (2004) 104 (11): 1835.

https://doi.org/10.1182/blood.V104.11.1835.1835

Published: 2004

NARROW

Oral Busulfan and Cyclophosphamide or IV Busulfan and Fludarabine for Allogeneic HSCT in Hematologic Malignancies?.

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Treating Hyperuricemia in Patients with Hematologic Malignancies.

Graft CD3+ Cell Content Affects Acute GVHD after Submyeloablative Allogeneic HSCT.

Ideal (IBW) Rather Than Actual (ABW) Body Weight Should Be Used To Calculate Cell Dose in Allogeneic HSCT.

Outcome of Submyeloablative Allogeneic HSCT for Hematologic Malignancies: Development of a Prognostic Model Based on Pre-Transplant Characteristics.

The Effect of the Platelet Content of Blood Stem Cell Grafts on GVHD.

Identifying Patients at Risk of Early Relapse after Submyeloablative Allogeneic HSCT.

Low-Dose Recombinante Urate Oxidase (Rasburicase) Is Effective in Hyperuricemia.

Pre-Transplant Variables Affecting the Outcome of Submyeloablative Allogeneic HSCT in Uniformly Treated Patients with Hematologic Malignancies.

Is a Younger 10-Allele-Matched Unrelated Donor (MUD) Better Than an Older 6-Antigen-Matched Sibling Donor (MSD) for Allogeneic HSCT?.

The CD34+ Cell Dose, Even in an "Acceptable" Range, Affects Outcome of Allogeneic Blood Stem Cell Transplantation.

Does Concomitant Methotrexate (MTX) and GM-CSF Administration after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Predispose to Thrombotic Microangiopathy (TMA)?.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only